CN106420454B - Composition for alleviating xerophthalmia and visual fatigue and its preparation method and application and ballpoint applicator - Google Patents
Composition for alleviating xerophthalmia and visual fatigue and its preparation method and application and ballpoint applicator Download PDFInfo
- Publication number
- CN106420454B CN106420454B CN201610862711.9A CN201610862711A CN106420454B CN 106420454 B CN106420454 B CN 106420454B CN 201610862711 A CN201610862711 A CN 201610862711A CN 106420454 B CN106420454 B CN 106420454B
- Authority
- CN
- China
- Prior art keywords
- composition
- xerophthalmia
- ballpoint
- visual fatigue
- alleviating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 208000005494 xerophthalmia Diseases 0.000 title claims abstract description 76
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 68
- 239000000341 volatile oil Substances 0.000 claims abstract description 50
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 34
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 34
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 34
- 239000006184 cosolvent Substances 0.000 claims abstract description 22
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 16
- 229930003268 Vitamin C Natural products 0.000 claims description 16
- 235000019154 vitamin C Nutrition 0.000 claims description 16
- 239000011718 vitamin C Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 9
- 239000000419 plant extract Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 16
- 230000028327 secretion Effects 0.000 abstract description 10
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 235000006708 antioxidants Nutrition 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000004438 eyesight Effects 0.000 abstract description 5
- 230000004089 microcirculation Effects 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 241000124008 Mammalia Species 0.000 abstract description 3
- 238000006467 substitution reaction Methods 0.000 abstract description 2
- 239000000284 extract Substances 0.000 description 40
- 239000003242 anti bacterial agent Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 15
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 13
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 13
- 235000007516 Chrysanthemum Nutrition 0.000 description 13
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 13
- 244000037364 Cinnamomum aromaticum Species 0.000 description 13
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 13
- 244000111489 Gardenia augusta Species 0.000 description 13
- 235000018958 Gardenia augusta Nutrition 0.000 description 13
- 244000178870 Lavandula angustifolia Species 0.000 description 13
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 13
- 240000003553 Leptospermum scoparium Species 0.000 description 13
- 235000015459 Lycium barbarum Nutrition 0.000 description 13
- 244000042664 Matricaria chamomilla Species 0.000 description 13
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 13
- 244000246386 Mentha pulegium Species 0.000 description 13
- 235000016257 Mentha pulegium Nutrition 0.000 description 13
- 235000004357 Mentha x piperita Nutrition 0.000 description 13
- 229940055416 blueberry extract Drugs 0.000 description 13
- 235000019216 blueberry extract Nutrition 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 239000001224 daucus carota l. seed absolute Substances 0.000 description 13
- 239000008169 grapeseed oil Substances 0.000 description 13
- 235000001050 hortel pimenta Nutrition 0.000 description 13
- 239000001102 lavandula vera Substances 0.000 description 13
- 235000018219 lavender Nutrition 0.000 description 13
- 239000003813 safflower oil Substances 0.000 description 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 12
- 244000020518 Carthamus tinctorius Species 0.000 description 12
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 229920002674 hyaluronan Polymers 0.000 description 12
- 229960003160 hyaluronic acid Drugs 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 239000002562 thickening agent Substances 0.000 description 8
- 206010013774 Dry eye Diseases 0.000 description 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 6
- 238000000540 analysis of variance Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000004706 scrotum Anatomy 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 239000000607 artificial tear Substances 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 238000007427 paired t-test Methods 0.000 description 4
- 229950008882 polysorbate Drugs 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 2
- 229940043234 carbomer-940 Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- -1 flavine ester Chemical class 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000013220 male mouse model Methods 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 101100256993 Rattus norvegicus Sit1 gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical compound [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008971 epithelial apoptosis Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H15/00—Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains
- A61H15/0092—Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains hand-held
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H15/00—Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains
- A61H15/02—Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains adapted for simultaneous treatment with light, heat or drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H15/00—Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains
- A61H2015/0007—Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains with balls or rollers rotating about their own axis
- A61H2015/0042—Balls or spheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0119—Support for the device
- A61H2201/0153—Support for the device hand-held
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/02—Head
- A61H2205/022—Face
- A61H2205/024—Eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
- A61K2800/874—Roll-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0612—Eyes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of for alleviating the composition of xerophthalmia and visual fatigue, which is characterized in that the composition includes oily phase, water phase, sodium hyaluronate solution, cosolvent and optional other auxiliary agents.Present invention uses the conventional oily phases of specific plants essential oil substitution, not only improve the storage stability of composition, while can play the effect for further improving xerophthalmia and visual fatigue.Further, it is also possible to significantly improve the basic lacrimal secretion and tear film stability of mammal.When cooperation ballpoint in use, massage eye circumference can also be played, alleviate the effects of visual fatigue, replenishing water and preserving moisture, anti-oxidant, activating microcirculation and removing stasis medicinal, improving eyesight；Simultaneously without any toxicity and side effects, have the characteristics that it is easy to carry, can use whenever and wherever possible.
Description
Technical field
The invention belongs to ophthalmic art field, it is related to a kind of ophthalmically acceptable health care and treatment preparation, more particularly, to a kind of use
In alleviation xerophthalmia and the composition of visual fatigue and its preparation method and application.Moreover, it relates to a kind of application group
Close the ballpoint applicator of object.
Background technique
Xerophthalmia refers to a kind of disease of the tear film relevant to ophthalmic uncomfortable as caused by a variety of causes and eye surface exception.
The normal main suit's eye dryness of such patient has the discomforts such as foreign body sensation, burn feeling, itch, photophobia, blurred vision, visual fatigue.Xerophthalmia
There are many inducement.Wherein, the stimulation of blue light is most commonly seen in life.Blue light is the high-energy visible light that wavelength is 400-500nm, general
Store-through is in all light sources of our daily lifes and work, such as all kinds of modern flat-panel displays, TFT film screen,
All contain a large amount of irregular frequency in the visible light that the various novel artificial light sources such as LED, fluorescent lamp, liquid crystal display issue
The energy of shortwave blue light, these shortwave blue lights is high, can penetrate the through retina of crystalline lens, cause photochemistry to damage it,
The oxidation for accelerating macular area cell, leads to macula retinae portion lesion.In addition to blue light, with the development of society, computer, hand
What machine, air-conditioning used increases, the exacerbation of air pollution, and the illness rate and consultation rate of xerophthalmia are gradually increasing, to people's
Life brings very important negative effect.Epidemiological survey shows that in 70 years old or more crowd, illness rate is up to
36.1%, wherein the disease incidence of male is 14.9%, and women 22.8%.Age in 30-40 years old crowd, suffers from more than 20%
Xerophthalmia.With the use of smart phone, patients with dry eye is increasing, and has the tendency that rejuvenation.
The general objective of dry eye treatment is to protect the visual function of patient, inhibits the inflammatory reaction of ocular, restores eye surface
Normal configuration and function.According to the different state of an illness, different treatment methods can be used.With what is recognized xerophthalmia pathogenesis
It deepens continuously, treatment can be continuous perfect.The treatment of xerophthalmia mainly uses artificial tears, and artificial tears' main component has
Cellulose family, glutinous polysaccharide, polyvinyl alcohol, polyacrylic, certain cell factors and some nutriments (such as vitamin A)
Deng.It opposite can improve ocular lubrication using artificial tears' treatment and increase ocular humidity, nutrition ocular and optic nerve.
With the research to xerophthalmia pathomechanism, many etiological treatments gradually start to apply, anti-inflammatory treatment can inhibit
Inflammatory factor mitigates the symptom of dry eyes.Topical application glucocorticosteroid hormone is to moderate, the subjective and objective clinic of severe dry eye patient
Its apparent improvement result of symptom is suitable for short, to reduce its side effect.If cyclosporine is a kind of immunomodulator, lead to
Retardance ocular Cellular Signaling Transduction Mediated is crossed, inhibits Apoptosis and plays its therapeutic effect.Volume fraction is 0.1% eye cyclosporin
It is reported and is shown with III clinical trial phase of emulsion, subject uses cyclosporine, and lacrimal secretion can obviously increase, and has good
Good safety and tolerance.In addition, FK506 and rapamycin, which can be transferred through different approaches, inhibits ocular inflammatory reaction and epithelium
Apoptosis, it inhibits ocular inflammatory effect stronger compared with cyclosporine, less side effects, it is possible to as new clinical treatment
The active drug of xerophthalmia.
However, artificial tears need to add preservative as a kind of eye sterile preparation, it can only respite eye disease
Shape is unsuitable for being used for a long time.And all there is different degrees of side effect in the drug therapy of xerophthalmia, in dry eye drugs treatment
It repeated because of ocular surface injury caused by dealed with medicine went or the case where aggravating dry eyes.Up to now, China there is no suitable for China
Xerophthalmia Normalized Treatment scheme.
For disadvantages mentioned above, there is an urgent need to find it is a kind of can satisfy application request for alleviating xerophthalmia and view
The composition and its method of administration of fatigue.
Summary of the invention
Inventors have found that use natural plant extracts, plants essential oil and vitamin needed by human as activity at
Point, homogeneous emulsion form is made, and be applied to eye circumference by way of ballpoint applicator, massage eye circumference, stimulation can be played
Lacrimal secretion alleviates the effects of visual fatigue, replenishing water and preserving moisture, anti-oxidant, activating microcirculation and removing stasis medicinal, improving eyesight；Simultaneously without any toxicity and side effects, have
Easy to carry, the features such as can using whenever and wherever possible.
The object of the invention first is that overcoming the deficiencies of the prior art and provide a kind of for alleviating the group of xerophthalmia and visual fatigue
Close object.
The second object of the present invention is to providing a kind of method for preparing the above-mentioned composition for being used to alleviate xerophthalmia and visual fatigue.
The three of the object of the invention are to provide above-mentioned for alleviating the purposes of the composition of xerophthalmia and visual fatigue.
The four of the object of the invention are to provide a kind of ballpoint applicator, comprising above-mentioned for alleviating the group of xerophthalmia and visual fatigue
Close object.
To achieve the above object, on the one hand, the present invention provides a kind of for alleviating the composition of xerophthalmia and visual fatigue,
The composition includes oily phase, water phase, sodium hyaluronate solution, cosolvent and optional other auxiliary agents.
In the present compositions, the oil mutually includes VitAVitE, lutein ester and plants essential oil；Its
In, plants essential oil is by grape seed oil, Lavender, Peppermint essential oil, carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile
Essential oil composition.
Based on the total weight of the composition, the content of the VitAVitE and lutein ester is respectively 0.01-
5%.Preferably, the content of the VitAVitE and lutein ester is respectively 0.02-3%；It is highly preferred that the dimension
The content of raw element A, vitamin E and lutein ester are respectively 0.03-1%；Most preferably, the VitAVitE and leaf
The content of flavine ester is respectively 0.05-0.5%.
Based on the total weight of the composition, the total content of the plants essential oil is 0.01-10%.Preferably, the plant
The total content of object essential oil is 0.02-8%；It is highly preferred that the total content of the plants essential oil is 0.05-5%；Most preferably, institute
The total content for stating plants essential oil is 0.1-4%.
In the present compositions, the water phase includes vitamin C and plant extracts；Wherein, the plant extract
Object is by chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower extract, blueberry extract group
At.
Based on the total weight of the composition, the ascorbic content is 0.1-5%.Preferably, the vitamin C
Content be 0.2-3%；It is highly preferred that the ascorbic content is 0.3-2%；Most preferably, described ascorbic to contain
Amount is 0.5-1%.
Based on the total weight of the composition, the total content of the plant extracts is 0.1-10%.Preferably, the plant
The total content of object extract is 0.3-8%；It is highly preferred that the total content of the plant extracts is 0.5-7%；Most preferably,
The total content of the plant extracts is 0.6-6%.
Based on the total weight of the composition, the content of the Sodium Hyaluronate is 0.02-5%.Preferably, described transparent
The content of matter acid sodium is 0.05-2%；It is highly preferred that the content of the Sodium Hyaluronate is 0.1-1%；Most preferably, described
The content of bright matter acid sodium is 0.2-0.5%.
The above effective component be assign composition alleviate xerophthalmia, visual fatigue, replenishing water and preserving moisture, anti-oxidant, activating microcirculation and removing stasis medicinal,
The ingredient of the properties such as improving eyesight.
In the present compositions, the cosolvent be selected from neopelex, lecithin, glycerol, propylene glycol,
Glycerin monostearate, sucrose ester, polysorbate, any one or more in triethanolamine.Preferably, the cosolvent choosing
From any one or more in neopelex, glycerol, propylene glycol, polysorbate, triethanolamine；It is highly preferred that
Any one or more of the cosolvent in glycerol, propylene glycol, polysorbate, triethanolamine；Most preferably, described to help
Any one or more of solvent in glycerol, propylene glycol, polysorbate.
Based on the total weight of the composition, the content of the cosolvent is 1-20%.Preferably, the cosolvent contains
Amount is 1.5-15%；Most preferably, the content of the cosolvent is 2-10%.
In the present compositions, other auxiliary agents include thickener, antibacterial agent and other additives.
In the present compositions, the thickener be selected from methylcellulose, sodium carboxymethylcellulose, Acritamer 940,
Sodium alginate, xanthan gum, lanolin, any one or more in polyvinyl alcohol.Preferably, the thickener is selected from carbomer
940, sodium alginate, xanthan gum, any one or more in lanolin；It is highly preferred that the thickener is selected from carbomer
940, xanthan gum, any one or more in lanolin；Most preferably, the thickener is in xanthan gum, lanolin
Any one or more.
Based on the total weight of the composition, the content of the thickener is 0.05-5%.Preferably, the thickener
Content is 0.08-4%；Most preferably, the content of the thickener is 0.1-3%.
In the present compositions, the antibacterial agent is selected from methylparaben, ethylparaben, sodium benzoate, sorb
Any one or more in sour potassium, Phenoxyethanol.Preferably, the antibacterial agent is selected from methylparaben, sodium benzoate, sorb
Any one or more in sour potassium, Phenoxyethanol；It is highly preferred that the antibacterial agent is selected from sodium benzoate, potassium sorbate, benzene oxygen
Any one or more in ethyl alcohol；Most preferably, the antibacterial agent in potassium sorbate, Phenoxyethanol any one or
It is a variety of.
Based on the total weight of the composition, the content of the antibacterial agent is 0.05-5.Preferably, the antibacterial agent contains
Amount is 0.1-2%；Most preferably, the content of the antibacterial agent is 0.2-1%.
In addition to ingredient listed above, composition of the invention can also further comprise other additives.Other additions
Agent includes antioxidant, moisturizer, natural fat, etc..
In a specific embodiment, the total weight based on the composition, composition of the invention include:
In a more specific embodiment, based on the total weight of the composition, composition of the invention includes:
In the present compositions, wet concentration is from pure water.
On the other hand, the present invention also provides a kind of sides for preparing the above-mentioned composition for being used to alleviate xerophthalmia and visual fatigue
Method, comprising the following steps:
A) it weighs Sodium Hyaluronate and is dissolved alone in water and obtain sodium hyaluronate solution；
B) VitAVitE, lutein ester and plants essential oil are uniformly mixed to obtain oily phase；
C) plant extracts water is dissolved and is uniformly mixed, add vitamin C, be uniformly mixed to obtain water phase；
D) homogeneous mixer is added in oily phase, water phase, sodium hyaluronate solution, cosolvent and optional other auxiliary agents to carry out
Mixing is to get the composition for alleviating xerophthalmia and visual fatigue.
Wherein, in step d), the temperature setting of the homogeneous mixer is 50-70 DEG C.Preferably, described to mix
The temperature setting of device is 60-70 DEG C；Most preferably, the temperature setting of the homogeneous mixer is 65-70 DEG C.
Wherein, in step d), the incorporation time is 1-60min.Preferably, the incorporation time is 3-30min；Most
Preferably, the incorporation time is 5-15min.
Another aspect, the present invention also provides above-mentioned for alleviating the purposes of the composition of xerophthalmia and visual fatigue.
Finally, the present invention provides a kind of ballpoint applicator, including ballpoint and ballpoint bottle, which is characterized in that the ballpoint
Bottle is containing above-mentioned for alleviating the composition of xerophthalmia and visual fatigue.
Compared with prior art, the present invention has following advantage:
1) present invention has used specific plants essential oil substitution routine for alleviating the composition of xerophthalmia and visual fatigue
Oily phase not only improves the storage stability of composition, while can play the effect for further improving xerophthalmia and visual fatigue.
2) present invention can significantly improve the basic tear of mammal for alleviating the composition of xerophthalmia and visual fatigue
Secretory volume (SIT) and tear film stability (BUT).
3) present invention is used for alleviating the composition cooperation ballpoint of xerophthalmia and visual fatigue, can also play massage eye
Alleviate the effects of visual fatigue, replenishing water and preserving moisture, anti-oxidant, activating microcirculation and removing stasis medicinal, improving eyesight in week；Simultaneously without any toxicity and side effects, there is carrying side
Just, the features such as can using whenever and wherever possible.
Specific embodiment
The invention will be further elucidated with reference to specific embodiments.It should be understood that these embodiments are merely to illustrate this hair
It is bright rather than limit the scope of the invention.In addition, it should also be understood that, after reading the contents of the present invention, those skilled in the art
The present invention can be made various changes or modifications, such equivalent forms are equally fallen within defined by the application the appended claims
Range.
Embodiment 1
Prescription, component and the weight percent that example 1 group closes object are as shown in table 1 below:
Table 1
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 60 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 2
The prescription of 2 composition of embodiment, component and weight percent are as shown in table 2 below:
Table 2
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 50 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 15min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 3
The prescription of 3 composition of embodiment, component and weight percent are as shown in table 3 below:
Table 3
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 65 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 4
The prescription of 4 composition of embodiment, component and weight percent are as shown in table 4 below:
Table 4
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 70 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 6min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 5
The prescription of 5 composition of embodiment, component and weight percent are as shown in table 5 below:
Table 5
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 65 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 6
The prescription of 6 composition of embodiment, component and weight percent are as shown in table 6 below:
Table 6
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 65 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 7
The prescription of 7 composition of embodiment, component and weight percent are as shown in table 7 below:
Table 7
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 65 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 8
The prescription of 8 composition of embodiment, component and weight percent are as shown in table 8 below:
Table 8
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 65 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 9
The prescription of 9 composition of embodiment, component and weight percent are as shown in table 9 below:
Table 9
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 65 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 10
The prescription of 10 composition of embodiment, component and weight percent are as shown in the following table 10:
Table 10
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 65 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 11
The prescription of 11 composition of embodiment, component and weight percent are as shown in table 11 below:
Table 11
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 65 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Embodiment 12
The prescription of 12 composition of embodiment, component and weight percent are as shown in table 12 below:
Table 12
Alleviate the essence ballpoint of xerophthalmia and visual fatigue the preparation method comprises the following steps:
A) Sodium Hyaluronate is weighed according to recipe quantity be dissolved alone in water obtain hyaluronic acid aqueous solution；
B) according to recipe quantity by VitAVitE, lutein ester, grape seed oil, Lavender, Peppermint essential oil,
Carrot seed oil, safflower seed oil, tea tree ethereal oil, chamomile essential oil are uniformly mixed to obtain oily phase；
C) chrysanthemum extract, cassia seed extract, capejasmine extract, Honegsukle flower P.E, safflower are mentioned according to recipe quantity
It takes object, blueberry extract water to dissolve and be uniformly mixed, adds recipe quantity vitamin C, be uniformly mixed to obtain water phase；
D) according to recipe quantity, at 70 DEG C, oily phase, water phase, sodium hyaluronate solution, cosolvent, antibacterial agent are added equal
Device is mixed, mixes 10min to get the composition for alleviating xerophthalmia and visual fatigue；
E) composition is distributed into the essence ballpoint for alleviating xerophthalmia and visual fatigue in ballpoint bottle.
Measure at a temperature of storage 8 week viscosity change of the composition at 40 DEG C.The result shows that compared with initial viscosity, 8 weeks
Final viscosity variation afterwards is no more than 10%.
Pharmacological evaluation
Inventor has studied ballpoint sample prepared by the embodiment of the present invention 1 to xerophthalmia hero mouse basis tear caused by castration
The influence of secretory volume, tear film stability.The present invention chooses healthy 1 monthly age Wistar male rat 45, and weight 0.2kg makees
With.Slit-lamp microscope, funduscopy anterior ocular segment and eyeground are without exception, and SchirmeierI tests (SIT) >=10mm/5min
It can be used with breakup time of tear film (BUT) >=10s animal.Experimental method method is as follows:
(1) animal packet is by Wistar male rat 45 (90), using random number method be divided into A1, B1, C1, A2,
Totally 9 groups of B2, C2, A3, B3, C3, every group 5 (10).It is respectively as follows: A and represents sham-operation blank group (hereinafter referred to as blank group)；B
Represent xerophthalmia model group (hereinafter referred to as model group)；C represents xerophthalmia model ballpoint sample administration group (hereinafter referred to as sample
Group)；1,2,3 administration time is respectively represented as January, 2 months, March.
(2) androgen levels decline leads to the preparation of xerophthalmia animal model
Make animal model: row bilateral orchidectomy (ORX): by the preoperative 12h of B1, B2, B3, C1, C2, C3 group experimental mouse
Fasting water, hind leg thigh lateral muscle meat iodophor disinfection, Ketamine Hydrochloride Inj. 30mg/kg weight intraperitoneal injection of anesthesia are male
Mouse takes dorsal position, and four limbs are opened and fixed, and lower abdomen agent of shedding is shedded, and scrotum subcutaneously adds with 2% lidocaine local anaesthesia, iodine
Volt disinfection, spreads aseptic towel list, side testis is squeezed into scrotum by abdominal cavity and is clutched, its sliding is not made.With disinfection blade by scrotum
An osculum is cut, testis is firmly squeezed out, spermatic vein and vas deferens, Testectomy and epididymis are ligatured, after continuously suturing skin of scrotum
Part applies tincture of iodine prevention infection.Another side testis and epididymis are cut off with method.A1, A2, A3 group only cut scrotum, not Testectomy, art
Skin of scrotum is continuously sutured afterwards.Preoperative 200,000 U of intramuscular injection mould hormone injection, postoperative continuous 3d intramuscular injection penicillin needle 200,000
U, prevention infection.
(3) hair that eye circumference is rejected before medication and dosage rat medication, exposes periocualr skin.A group, B are wiped with distilled water
Eye circumference is applied, C group rubs eye circumference with ballpoint sample.Erasing is eyes, 3 times a day, every time under erasing 3.A1, B1, C1 group are persistently given
It is put to death after medicine 1 month, execution, A3, B3, C3 group are put to death after being administered continuously 3 months after A2, B2, C2 group are administered continuously 2 months.
(4) materials are preceding to each before grouping, after the completion of last dose for basic lacrimal secretion, tear film stability measurement
The male mouse of group carries out SchirmerI test (SIT) respectively and breakup time of tear film (BUT) checks.
Experimental result is as follows:
(1) influence of the ballpoint sample to rat basis lacrimal secretion (SIT)
As seen from Table 13: blank group (A1, A2, A3) SIT measured value compares: Analysis of variance, between A1, A2, A3 each group
Difference is not statistically significant (P > 0.01), through itself front and back paired t-test, after each group distilled water is wiped at the moment, rat SIT difference
Not statistically significant (equal P > 0.05).To positive controls compared with blank group SIT measured value: being examined through t, A1 and B1, A2
With B2, difference is statistically significant (equal P < 0.04) between A3 and C3.Model group (B1, B2, B3) SIT measured value compares: warp
Itself front and back paired t-test, 1 after male mouse model group castration, 2, basic lacrimal secretion significantly reduces after March, the wet long contracting of filter paper
It is short, it is statistically significant (equal P < 0.01) with comparing difference before castration；Basic tear after another Analysis of variance, with B1 group castration January
Liquid secretory volume compares, and castration 2 months are lower (P < 0.05) with B2, B3 group lacrimal secretion amount in castration March, it is seen that after castration, tear
The basal secretion amount of gland is reduced with the growth of time.Sample sets (C1, C2, C3) SIT measured value compares: ballpoint administration group with
Model group (C1 is compared with B1, C2 and B2, C3 and B3) SIT measured value: with the wet a length of covariant of test paper, through the analysis of covariance, C1,
After C2, C3 group castration after ballpoint applies sample, basic lacrimal secretion increases, the wet length of filter paper and corresponding model group B1, B2,
It is obvious (equal P < 0.05) that B3 group compares growth.
13 ballpoint of table applies sample to different time sections after the administration of rat each group
The influence (n=10, x ± s, mm) of SIT measured value
Note: model group P < 0.01 * * compared with blank group；Sample sets P < 0.05 ★ compared with model group
(2) influence of the ballpoint sample to rat tear film stability (BUT)
As seen from Table 14: blank group (A1, A2, A3) BUT measured value compares: Analysis of variance, between A1, A2, A3 each group
Difference is not statistically significant (P > 0.05), and through itself front and back paired t-test, perioperatively, rat BUT difference is equal for each group
Not statistically significant (equal P > 0.05).Model group is examined compared with blank group BUT measured value through t, A1 and B1, A2 and B2, A3 with
Difference is statistically significant (equal P < 0.01) between B3.Model group (B1, B2, B3) BUT measured value compares: matching through itself front and back
T to be examined, tear film stability is decreased obviously after 1,2,3 month after male mouse model group castration, and breakup time of tear film is obviously shortened, with
Comparing difference is statistically significant (equal P < 0.01) before castration, in addition tear film stability after Analysis of variance, with B1 group castration 1 month
Property compares, and the breakup time of tear film of castration 3 months B3 groups is lower (P < 0.05), it is seen that after castration, tear film stability with
The growth of time and the trend that reduction is gradually presented.Sample sets (C1, C2, C3) BUT measured value compares: through ballpoint after male mouse castration
It applies, Analysis of variance, BUT measured value difference is not statistically significant (P > 0.05) between C1, C2, C3 each group, and through certainly
Paired t-test before and after body, each group perioperatively, rat BUT significant difference (equal P > 0.05).Sample sets and model group (C1 and B1,
C2 is compared with B2, C3 and B3) BUT measured value: breakup time of tear film is covariant, through the analysis of covariance, C1, C2, C3 group castration
After applying sample by ballpoint, tear film stability increases, and breakup time of tear film increases compared with corresponding model group B1, B2, B3 group
Length is obvious (equal P < 0.05), in addition Analysis of variance, after being applied sample 1 month with C1 group castration ballpoint compared with tear film stability,
The breakup time of tear film of castration 3 months C3 groups wants relatively high (P < 0.05), it is seen that after castration, ballpoint sample is to maintenance
Increased trend is gradually presented with the growth of time in the ability of tear film stability.Pharmacological experiment study proves institute of the present invention
The ballpoint sample of offer has good relaxation effect to xerophthalmia.
14 ballpoint of table applies sample to different time sections after the administration of rat each group
The influence (n=10, x ± s, s) of BUT measured value
Note: model group P < 0.01 * * compared with blank group；Sample sets P < 0.05 ★ compared with model group
The above result shows that the present invention can significantly improve mammal for alleviating xerophthalmia and the composition of visual fatigue
Basic lacrimal secretion (SIT) and tear film stability (BUT).
In addition, the present invention is used to alleviate xerophthalmia and the composition cooperation ballpoint of visual fatigue uses, massage can also be played
Eye circumference alleviates the effects of visual fatigue, replenishing water and preserving moisture, anti-oxidant, activating microcirculation and removing stasis medicinal, improving eyesight；Simultaneously without any toxicity and side effects, have and carry
Conveniently, the features such as can using whenever and wherever possible.
The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention, for the skill of this field
For art personnel, the invention may be variously modified and varied.All within the spirits and principles of the present invention, made any to repair
Change, equivalent replacement, improvement etc., is all included in the scope of protection of the present invention.
Claims (4)
1. a kind of for alleviating the composition of xerophthalmia and visual fatigue, which is characterized in that the total weight based on the composition, group
Closing object includes:
2. a kind of method for preparing composition described in claim 1, comprising the following steps:
A) it weighs Sodium Hyaluronate and is dissolved alone in water and obtain sodium hyaluronate solution；
B) VitAVitE, lutein ester and plants essential oil are uniformly mixed to obtain oily phase；
C) plant extracts water is dissolved and is uniformly mixed, add vitamin C, be uniformly mixed to obtain water phase；
D) homogeneous mixer is added in oily phase, water phase, sodium hyaluronate solution, cosolvent and optional other auxiliary agents to mix
It closes to get the composition for alleviating xerophthalmia and visual fatigue.
3. the purposes of composition described in claim 1, which is characterized in that for alleviating xerophthalmia and visual fatigue.
4. a kind of ballpoint applicator, including ballpoint and ballpoint bottle, which is characterized in that the ballpoint bottle contains described in claim 1
Composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610862711.9A CN106420454B (en) | 2016-09-28 | 2016-09-28 | Composition for alleviating xerophthalmia and visual fatigue and its preparation method and application and ballpoint applicator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610862711.9A CN106420454B (en) | 2016-09-28 | 2016-09-28 | Composition for alleviating xerophthalmia and visual fatigue and its preparation method and application and ballpoint applicator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106420454A CN106420454A (en) | 2017-02-22 |
| CN106420454B true CN106420454B (en) | 2019-02-22 |
Family
ID=58170918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610862711.9A Active CN106420454B (en) | 2016-09-28 | 2016-09-28 | Composition for alleviating xerophthalmia and visual fatigue and its preparation method and application and ballpoint applicator |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420454B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108066183A (en) * | 2017-12-27 | 2018-05-25 | 广州市澳键丰泽生物科技股份有限公司 | Eye glue preparation containing plants essential oil and its preparation method and application |
| CN108125829A (en) * | 2017-12-27 | 2018-06-08 | 广州市澳键丰泽生物科技股份有限公司 | A kind of preparation containing plants essential oil and its preparation method and application |
| CN112006282A (en) * | 2020-09-04 | 2020-12-01 | 北京瑞济善健康科技有限公司 | Composition for repairing diabetic complications and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850062A (en) * | 2006-02-24 | 2006-10-25 | 无锡杰西医药科技有限公司 | Fatty acid eye nano preparations for dry eye disease |
| CN102657739A (en) * | 2012-05-29 | 2012-09-12 | 翟佳滨 | Eyesight adjusting ointment for myopia |
| CN105662911A (en) * | 2016-03-02 | 2016-06-15 | 佛山市万盈化妆品有限公司 | Ocular region roll-on essence containing bone collagen |
| CN105687296A (en) * | 2016-01-31 | 2016-06-22 | 杭州睩客科技有限公司 | Volatile medicine with eye health-care effect |
-
2016
- 2016-09-28 CN CN201610862711.9A patent/CN106420454B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850062A (en) * | 2006-02-24 | 2006-10-25 | 无锡杰西医药科技有限公司 | Fatty acid eye nano preparations for dry eye disease |
| CN102657739A (en) * | 2012-05-29 | 2012-09-12 | 翟佳滨 | Eyesight adjusting ointment for myopia |
| CN105687296A (en) * | 2016-01-31 | 2016-06-22 | 杭州睩客科技有限公司 | Volatile medicine with eye health-care effect |
| CN105662911A (en) * | 2016-03-02 | 2016-06-15 | 佛山市万盈化妆品有限公司 | Ocular region roll-on essence containing bone collagen |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106420454A (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9925201B2 (en) | Compositions and treatment for eye diseases and disorders | |
| CN106420454B (en) | Composition for alleviating xerophthalmia and visual fatigue and its preparation method and application and ballpoint applicator | |
| CN104984158B (en) | A kind of eye sticker and its preparation process | |
| JP5897164B2 (en) | Composition for external use | |
| JP2021505650A (en) | Ophthalmic drug preparations and their use | |
| JP2019059757A (en) | Aqueous composition for ophthalmological use or otolaryngological use | |
| WO2017130130A1 (en) | Nutritional supplement for maintaining the state of health of the eye | |
| CN106963770B (en) | Eye drops for preventing and treating keratoconjunctivitis sicca and preparation method and application thereof | |
| CN107412211A (en) | Aminoadamantan amine single nitric acid ester type compound ophthalmic composition and its preparation and application | |
| WO2023113587A1 (en) | Lipid-based formulation for topical ophthalmic use, containing hop flower extract | |
| WO2008142619A1 (en) | Use of herbal compositions in the protection and enhancement of extracellular matrix components | |
| CN112263545A (en) | Ophthalmic composition and preparation method and application thereof | |
| CN117298073B (en) | Transdermal drug delivery pharmaceutical composition for treating xerophthalmia | |
| CN104127535B (en) | A kind of pharmaceutical composition and application thereof for the treatment of xerophthalmia | |
| CN102078287B (en) | Ophthalmic gel of artificial musk and preparation method thereof | |
| Kocsard | Three cases of exudative chronic discoid and lichenoid dermatosis (Sulzberger and Garbe)(in Shanghai) | |
| RU2733392C1 (en) | Combined ophthalmic agent | |
| TWI632913B (en) | Compositions and treatment for eye diseases and disorders | |
| DE10360425A1 (en) | Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications | |
| CN116077407A (en) | Eye health care massage composition, preparation method and application thereof | |
| CN117883380A (en) | Transdermal emulsion for treating xerophthalmia | |
| Franke et al. | Neuromodulation for Treatment of Dry Eye | |
| KR20200077765A (en) | Composition for preventing and treating dry eye syndrome comprising selenium and propolis as active ingredients | |
| IT201800007592A1 (en) | Nutritional supplement comprising Emblica officinalis | |
| CN105214092A (en) | RHuIL-1Ra and compositions thereof and medicinal usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170222 Assignee: Beijing Sihuan Biopharmaceutical Co., Ltd. Assignor: Beijing Ruiji good health science and Technology Co Ltd Contract record no.: 2019110000004 Denomination of invention: Composition for alleviating dry eyes and visual fatigue, preparation method and application of composition, and roll applicator Granted publication date: 20190222 License type: Exclusive License Record date: 20190506 |